



## Revenue at 30 June 2015

**€227.3 Million; +8.1% at constant exchange rates**

**Villepinte, 28 July 2015 - Guerbet** (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting second quarter revenue up by 4.4%, at constant exchange rates. Cumulative revenue totalled €227.3 million at the end of June 2015, up by 12.2%, or +8.1% excluding exchange rate effects.

### Consolidated Group revenue (IFRS)

In millions of euros	1st half 2015	1st half 2014	Change	Q2 2015	Q2 2014	Change
Sales in Europe	158.7	144.0	10.2%	80.0	72.0	11.1%
Sales in Other Markets	68.6	58.6	17.0%	35.1	34.1	3.2%
<b>Total</b>	<b>227.3</b>	202.6	12.2%	<b>115.1</b>	106.1	8.6%

### Strong growth in Europe, expansion of Dotarem<sup>®</sup> sales in the United States

In Europe, second quarter revenue totalled €80.0 million, an increase of 11.1%. At constant exchange rates, cumulative revenue for the first half of the year amounted to €155.2 million, up by 8.9%. This increase especially relates to Germany, the United Kingdom and Turkey. Growth in Europe was 10.2% at current exchange rates, with a favourable exchange rate effect mainly in Switzerland.

On Other Markets, second quarter revenue amounted to €35.1 million, up by 3.2%, and continued to benefit from the strong growth of **Dotarem<sup>®</sup>** in the United States, which offset a slowdown in Asia and Brazil. The increase remained steady over the first half at +17.0%, driven by an excellent first quarter.

## Press release

### Strong contribution to growth by Xenetix® and Dotarem®

With €50.4 million in revenue in the second quarter, up by 23.3% compared with the same period in 2014, the MRI segment relied on the good performance of **Dotarem®**, particularly in the USA and Germany. On the first half, the MRI segment grew by 20.8% to €97.7 million.

Second quarter revenue in the X-Ray segment totalled €49.5 million compared with €49.3 million in the same period last year. Sales of **Xenetix®** increased, offsetting the decrease in the segment's other products. The segment's sales grew by 1.8% in the first half to €98.1 million.

On the IRT segment, cumulative sales of **Lipiodol®** and **Patent Blue V** were €21.5 million at 30 June, a 37.0% increase. Lastly, the medical devices (MD) segment, now called **Imaging Solutions and Services** (ISS), posted 7.6% growth with €9.0 million in revenue.

### 2015 outlook

After a successful first half for the Group, Guerbet will continue to pay close attention to the launch of **Dotarem®** generics in Europe as well as the increased production rates of the new **ScanBag®** filling line, which made encouraging but insufficient progress over the last three months.

In the end, the Group has confirmed its organic sales growth in 2015.

The acquisition of Mackinkrodt's "contrast agents and injection systems" business, announced this morning, will significantly change the company's profile: with more than €800 million in 2014 pro forma revenue and nearly 2,500 employees, Guerbet doubles its revenue, expands its geographic footprint and strengthens its positions in both contrast agents and injection solutions.

---

### Upcoming events:

- Publication of 2015 half-yearly consolidated accounts: 29 September 2015 before trading

# Press release

## About Guerbet

---

Guerbet is a pioneer in the contrast agent field, with nearly 90 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 9% of its sales each year. Guerbet (GBT) is listed on NYSE Euronext Paris (Segment B – Mid Caps) and generated revenue of €409 million in 2014. It had a total workforce of 1,461 employees at 31 December 2014.

For more information about **Guerbet**, please go to [www.guerbet.com](http://www.guerbet.com)

## Contacts

---

### **Guerbet**

**Jean-François Le Martret**

*Chief Financial Officer*

01 45 91 50 00

### **Actifin**

**Christophe de Lylle/Benjamin Lehari**

01 56 88 11 11

[cdelylle@actifin.fr](mailto:cdelylle@actifin.fr)/[blehari@actifin.fr](mailto:blehari@actifin.fr)

*Press*

**Jennifer Jullia**

01 56 88 11 19

[jjullia@actifin.fr](mailto:jjullia@actifin.fr)